Fig. 4From: From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boardsHeatmap representation of the distribution of identified actionable variants in TCGA cohort. Somatic alterations of each sample (3184 samples) were analyzed as depicted in Fig. 1 and the resulting biomarker–drug associations were assigned to one of the six levels of evidence. Evidence in wild-type variants and resistances are not included in this representation (unless if the evidence is in level A1, e.g., NRAS, KRAS wild type in colorectal cancer). a The percentage of patients with at least one actionable variant at each level of evidence. b The cumulative percentage of patients with at least one actionable variant at increasing levels of evidence (from A1 to B3, x-axis). c Average (± standard deviation (SD)) number of actionable genes per patient at each level of evidence. d Combination of the data shown in a–c panels depicted for the whole cohort, no distinction among cancer typesBack to article page